May 19, 2025, 20:57

2025 PCF TACTICAL Awards

The Prostate Cancer Foundation (PCF) is inviting Letters of Intent for the 2025 TACTICAL Awards (Therapy ACceleration To Intercept CAncer Lethality). These grants support high-risk, high-reward projects focused on developing next-generation therapies for lethal prostate cancer. International academic teams are encouraged to apply.

Eligibility Criteria

Teams must include at least five investigators from a minimum of four nonprofit academic institutions.
At least two investigators must be early-career researchers (within six years of their terminal degree).
Young investigators must not have received more than 2 million US Dollars in direct research funding.
For-profit and government institution researchers are not eligible.
Multidisciplinary, diverse, and inclusive team structures are favored.
Only academic institutions are eligible to receive funds.

Funding Details

Grant amount: 5 million to 10 million US Dollars per award
Duration: 3 to 5 years
Institutional indirect costs capped at 10%
Clinical trial costs are not eligible, but correlative studies linked to trials are encouraged

Research Topics of Interest

Theranostics
Novel therapeutics for undruggable targets
Precision biotechnology innovation
First-in-field immunotherapies for prostate cancer
Artificial intelligence and machine learning in oncology
Host microbiome and tumor metabolism interactions

Key Deadlines

Letter of Intent (LOI) due: May 19, 2025
Notification to submit full application: May 28, 2025
Full application deadline: July 9, 2025 at 3:00 p.m. EDT

Where to Apply

Submit LOI by email: [email protected]
Submit full applications (by invitation only): https://pcf.smartsimple.com
Additional information: https://pcf.org/open-rfas

AI in cancer biotech innovation cancer cancer research funding global research funding immunotherapy development lethal prostate cancer OncoDaily Oncology oncology research PCF Prostate Cancer Foundation prostate cancer grants tactical awards Young Investigator Grants

Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC